| Catalog No. | Size | Price (USD) |
| 14927-T48-50 | 50 µL | $147.96 |
| 14927-T48-100 | 100 µL | $251.64 |
| 14927-T48-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-EIF5A2 Antibody, Rabbit Polyclonal |
| Validated applications | WB (FAQ Protocol), ELISA (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human EIF5A2 |
| Immunogen | Recombinant Human EIF5A2 Protein (Catalog#14927-H07E) |
| Preparation | Produced in rabbits immunized with purified, recombinant Human EIF5A2 (rh EIF5A2; Catalog#14927-H07E; Q9GZV4; Met1-Lys153). EIF5A2 specific IgG was purified by Human EIF5A2 affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A & Antigen Affinity |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-EIF-5A2 Antibody; Anti-eIF5AII Antibody
Image / Experimental Information
| Image 1 Description | Anti-EIF5A2 rabbit polyclonal antibody at 1:500 dilution Lane A: HeLa Whole Cell Lysate Lane B: A431 Whole Cell Lysate Lane C: Caco-2 Whole Cell Lysate Lane D: HepG2 Whole Cell Lysate Lysates/proteins at 30 μg per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size:14 kDa Observed band size:18 kDa |
| Image 1 Alt Text | Human EIF5A2 Western blot (WB) 33449 |
| Image 1 URL | Source image |
Background Information
| Full Name | eukaryotic translation initiation factor 5A2 |
| Description | Eukaryotic translation initiation factor 5A2 (EIF5A2) has been demonstrated to be upregulated in numerous types of human cancer and is associated with cancer progression. Silencing of EIF5A2 in the NSCLC cells resulted in the downregulation of the tumorigenic proteins, apoptosis regulator Bcl-2 and myc proto-oncogene protein, and upregulation of E-cadherin, suggesting that EIF5A2 promotes proliferation and metastasis through these proteins. EIF5A2 may therefore serve as a novel therapeutic target for the treatment of NSCLC. EIF5A2 might be a novel therapeutic target for the inhibition of NPC progress. EIF5A2 overexpression may contribute to cancer progression and poor prognosis, it could be a novel potential prognostic marker for FIGO stage I-II cervical cancer. EIF5A2 upregulation plays an important oncogenic role in gastric cancer. EIF5A2 may represent a new predictor for poor survival and is a potential therapeutic target for gastric cancer. The eukaryotic initiation factor 5A2 (EIF5A2) over-expression enhances HCC cell metastasis. EIF5A2, as a target of PI3K/Akt, promotes melanoma cell invasion and may serve as a promising prognostic marker and a potential therapeutic target for melanoma. |
-HD15OC1806-WB.png){kind=link}